Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Jonathan Young. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Jonathan Young har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:AKRO / Akero Therapeutics, Inc. Chief Operating Officer 0
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Jonathan Young. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Jonathan Young som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-12-09 2025-12-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
D - Sale to Issuer -47.573 0 -100,00
2025-12-09 2025-12-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
D - Sale to Issuer -20.000 0 -100,00
2025-12-09 2025-12-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
D - Sale to Issuer -20.000 0 -100,00
2025-12-09 2025-12-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
D - Sale to Issuer -20.000 0 -100,00
2025-12-09 2025-12-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
D - Sale to Issuer -152.616 0 -100,00
2025-11-26 2025-11-26 4 AKRO Akero Therapeutics, Inc.
Common Stock
G - Gift -9.259 200.189 -4,42
2025-11-26 2025-11-24 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 4.739 209.448 2,31 21,10 99.993 4.419.353
2025-11-26 2025-11-24 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 3.527 204.709 1,75 28,35 99.990 5.803.500
2025-11-26 2025-11-24 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 4.284 201.182 2,18 21,09 90.350 4.242.928
2025-10-03 2025-10-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -4.201 196.898 -2,09 47,98 -201.581 9.447.954
2025-10-03 2025-10-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -8.299 201.099 -3,96 47,64 -395.398 9.581.161
2025-10-03 2025-10-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 209.398 6,35 21,10 263.750 4.418.298
2025-09-12 2025-09-11 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -586 196.898 -0,30 43,02 -25.210 8.470.552
2025-09-04 2025-09-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -61 197.484 -0,03 47,58 -2.902 9.396.289
2025-09-04 2025-09-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -2.739 197.545 -1,37 47,14 -129.106 9.311.481
2025-09-04 2025-09-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -9.700 200.284 -4,62 45,78 -444.027 9.168.200
2025-09-04 2025-09-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 209.984 6,33 21,10 263.750 4.430.662
2025-08-13 2025-08-12 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -1.349 197.484 -0,68 48,32 -65.189 9.543.217
2025-08-13 2025-08-12 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -11.151 198.833 -5,31 47,72 -532.137 9.488.510
2025-08-13 2025-08-12 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 209.984 6,33 21,10 263.750 4.430.662
2025-07-02 2025-06-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 890 197.484 0,45 23,87 21.243 4.713.548
2025-06-20 2025-06-18 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -1.453 196.594 -0,73 54,84 -79.683 10.781.215
2025-06-12 2025-06-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -2.493 198.047 -1,24 53,99 -134.605 10.693.152
2025-03-14 2025-03-12 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -607 200.540 -0,30 44,88 -27.242 9.000.235
2025-03-05 2025-03-04 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -38.553 201.147 -16,08 45,07 -1.737.622 9.065.896
2025-03-05 2025-03-04 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -11.447 239.700 -4,56 44,17 -505.591 10.587.070
2025-02-05 2025-02-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -4.900 251.147 -1,91 54,06 -264.879 13.576.253
2025-02-05 2025-02-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -5.100 256.047 -1,95 53,56 -273.182 13.715.158
2025-01-27 2025-01-24 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 43.064 261.147 19,75 6,36 274.059 1.661.940
2025-01-06 2025-01-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -10.000 218.083 -4,38 28,03 -280.330 6.113.521
2024-12-18 2024-12-16 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 24.300 228.083 11,92
2024-12-12 2024-12-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -2.503 203.783 -1,21 30,79 -77.067 6.274.479
2024-12-04 2024-12-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -10.000 206.286 -4,62 32,13 -321.310 6.628.175
2024-11-05 2024-11-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -292 216.286 -0,13 32,94 -9.618 7.123.812
2024-11-05 2024-11-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -15.481 216.578 -6,67 32,27 -499.525 6.988.322
2024-11-05 2024-11-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -34.943 232.059 -13,09 31,25 -1.092.109 7.252.772
2024-11-05 2024-11-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 40.716 267.002 17,99 21,09 858.700 5.631.072
2024-10-16 2024-10-14 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -40.000 226.286 -15,02 30,15 -1.206.080 6.822.975
2024-10-16 2024-10-14 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 40.000 266.286 17,68 21,09 843.600 5.615.972
2024-10-03 2024-10-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -10.000 226.286 -4,23 28,18 -281.770 6.376.061
2024-09-13 2024-09-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -568 236.286 -0,24 26,18 -14.870 6.185.967
2024-09-05 2024-09-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -1.290 236.854 -0,54 27,58 -35.573 6.531.486
2024-09-05 2024-09-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.710 238.144 -1,53 26,42 -98.014 6.291.526
2024-08-02 2024-08-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -1.969 241.854 -0,81 27,23 -53.616 6.585.684
2024-08-02 2024-08-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.031 243.823 -1,23 26,44 -80.140 6.446.680
2024-07-02 2024-07-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -5.000 246.854 -1,99 23,40 -117.020 5.777.371
2024-07-02 2024-06-28 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 1.064 251.854 0,42 19,94 21.217 5.022.221
2024-06-13 2024-06-11 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -2.516 250.790 -0,99 22,64 -56.965 5.678.136
2024-06-05 2024-06-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -5.000 253.306 -1,94 19,29 -96.440 4.885.766
2024-05-02 2024-05-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -5.000 258.306 -1,90 20,15 -100.750 5.204.840
2024-04-03 2024-04-01 4 AKRO Akero Therapeutics, Inc.
Common Stoek
S - Sale X -400 263.306 -0,15 25,02 -10.010 6.589.233
2024-04-03 2024-04-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -4.600 263.706 -1,71 24,33 -111.903 6.415.097
2024-03-15 2024-03-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -651 268.306 -0,24 28,33 -18.443 7.601.109
2024-03-05 2024-03-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 83.321 268.957 44,88 0,62 51.242 165.409
2023-12-29 2023-12-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -5.414 185.131 -2,84 24,00 -129.936 4.443.144
2023-12-29 2023-12-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 5.414 190.545 2,92 6,36 34.433 1.211.866
2023-12-18 2023-12-14 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -543 185.131 -0,29 20,76 -11.273 3.843.320
2023-12-12 2023-12-08 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 32.497 185.674 21,22
2023-11-21 2023-11-17 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale -30.000 153.177 -16,38 14,68 -440.259 2.247.918
2023-10-04 2023-10-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -490 183.177 -0,27 51,10 -25.039 9.360.345
2023-10-04 2023-10-02 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 490 183.667 0,27 21,10 10.339 3.875.374
2023-09-25 2023-09-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -562 183.177 -0,31 50,34 -28.291 9.221.130
2023-06-15 2023-06-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -538 183.739 -0,29 55,16 -29.676 10.135.043
2023-03-14 2023-03-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
F - Taxes -634 184.277 -0,34 43,47 -27.560 8.010.521
2023-01-05 2023-01-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -8.777 184.911 -4,53 54,64 -479.560 10.103.223
2023-01-05 2023-01-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 8.777 193.688 4,75 0,62 5.398 119.118
2022-12-28 2022-12-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -12.500 182.449 -6,41 49,57 -619.609 9.043.760
2022-12-28 2022-12-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 11.778 194.949 6,43 6,36 74.908 1.239.876
2022-12-28 2022-12-27 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 722 183.171 0,40 0,62 444 112.650
2022-12-13 2022-12-09 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 19.195 182.449 11,76
2022-10-27 2022-10-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -12.500 163.254 -7,11 44,72 -558.944 7.299.984
2022-10-27 2022-10-25 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise X 12.500 175.754 7,66 6,36 79.500 1.117.795
2022-01-11 2022-01-07 4 AKRO Akero Therapeutics, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -1.448 92.820 -1,54
2022-01-11 2022-01-07 4 AKRO Akero Therapeutics, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -26.296 0 -100,00
2022-01-11 2022-01-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 27.744 163.254 20,47 0,62 17.063 100.401
2021-12-10 2021-12-08 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 87.221 87.221
2021-11-05 2021-11-04 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -6.220 135.510 -4,39 24,33 -151.333 3.296.958
2021-11-05 2021-11-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -18.780 141.730 -11,70 24,27 -455.791 3.439.787
2021-09-03 2021-09-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -12.500 160.510 -7,23 24,04 -300.500 3.858.660
2021-07-19 2021-07-15 4 AKRO Akero Therapeutics, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -9.000 26.296 -25,50
2021-07-19 2021-07-15 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 9.000 173.010 5,49 0,62 5.535 106.401
2021-06-02 2021-06-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.055 164.010 -1,83 26,24 -80.151 4.302.966
2021-05-04 2021-05-03 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.055 167.065 -1,80 30,56 -93.361 5.105.506
2021-04-05 2021-04-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -3.055 170.120 -1,76 28,75 -87.828 4.890.746
2021-03-02 2021-03-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -200 173.175 -0,12 31,17 -6.234 5.397.865
2021-03-02 2021-03-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -2.855 173.375 -1,62 30,43 -86.878 5.275.801
2021-02-02 2021-02-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -200 176.230 -0,11 29,92 -5.984 5.272.802
2021-02-02 2021-02-01 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -2.855 176.430 -1,59 29,19 -83.337 5.149.992
2021-01-11 2021-01-08 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -10.000 179.285 -5,28 28,12 -281.200 5.041.494
2021-01-11 2021-01-07 4 AKRO Akero Therapeutics, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -7.500 35.296 -17,53
2021-01-11 2021-01-07 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 7.500 189.285 4,13 0,62 4.612 116.410
2021-01-06 2021-01-04 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -100 181.785 -0,05 26,00 -2.600 4.726.410
2021-01-06 2021-01-04 4 AKRO Akero Therapeutics, Inc.
Common Stock
S - Sale X -2.960 181.885 -1,60 25,27 -74.799 4.596.234
2020-12-09 2020-12-08 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 77.580 77.580
2020-12-09 2020-06-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
A - Award 1.245 184.845 0,68 17,07 21.250 3.154.934
2020-03-16 2020-03-13 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -6.082 94.268 -6,06
2020-03-16 2020-03-13 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -5.035 42.796 -10,53
2020-03-16 2020-03-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 6.082 183.600 3,43 0,62 3.740 112.914
2020-03-16 2020-03-13 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 5.035 177.518 2,92 0,62 3.097 109.174
2020-01-10 2020-01-10 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise 21.286 100.350 26,92
2020-01-10 2020-01-10 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise 17.621 47.831 58,33
2020-01-10 2020-01-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 21.286 232.483 10,08 0,62 13.091 142.977
2020-01-10 2020-01-10 4 AKRO Akero Therapeutics, Inc.
Common Stock
M - Exercise 17.621 211.197 9,10 0,62 10.837 129.886
2019-12-31 2019-12-30 4 AKRO Akero Therapeutics, Inc.
Common Stock
W - Other 667 193.576 0,35
2019-12-13 2019-12-13 4 AKRO Akero Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 85.000 85.000
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
445.818
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
272.909
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
272.909
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
272.909
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
445.818
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
272.909
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
272.909
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
272.909
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
445.818
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
272.909
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
272.909
2019-06-19 3 AKRO Akero Therapeutics, Inc.
Common Stock
272.909
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)